The global in-vitro diagnostics infectious diseases market size is likely to
reach USD 31.45 billion by 2026, according to a new report by Grand View
Research, Inc., experiencing a CAGR of 6.7% during the forecast period.
Increasing geriatric population and rising consumer awareness regarding the
merits of IVD tests are expected to drive the IVD infectious diseases market.
Growing prevalence of target diseases,
health awareness, and high demand for self-care medical devices are estimated
to accentuate market growth over the forecast period. Moreover, introduction of
technologically advanced products with improved sensitivity, speed, and
user-friendliness are anticipated to increase the adoption of in-vitro
diagnostics for infectious diseases in the next few years.
Key IVD techniques include immunochemistry
assays, such as Enzyme-linked Immunosorbent Assay (ELISA) and
Immuno-agglutination. These are widely used in clinical laboratories and
diagnostic centers for detecting infectious microorganisms such as bacteria and
virus in patient samples.
North America dominated the market,
supported by presence of sophisticated healthcare infrastructure, government
initiatives pertaining to research & development activities, and high
awareness levels of patients and practitioners. The Asia Pacific IVD infectious
diseases market is projected to witness the fastest growth over the forecast
period.
Access Research Report of IVD Infectious Diseases Market @ https://www.grandviewresearch.com/industry-analysis/ivd-infectious-disease-market
Further key findings from the report suggest:
· Introduction of technologies such as qPCR
and ELISA has enhanced usage rates of IVD products for infectious disease
testing
· High unmet consumer needs, supported by
rising disposable income and awareness levels in emerging markets, is a key
growth stimulant
· Immunochemistry assays, such as ELISA and
chemiluminescence immunoassays, are projected to be widely used over the
forecast period
· Molecular diagnostics is poised to witness
strong growth, driven by wide adoption and improved accuracy levels
· Key players in the market include Becton
Dickinson; bioMerieux; Abbott Laboratories; Quidel Corporation; Alere Inc.;
Orasure Technologies, Inc.; Hologic Inc.; Cepheid; Qiagen N.V.; Roche
Diagnostics; Siemens Healthcare; and Bio-Rad Laboratories, Inc.
Grand View Research has segmented the
global IVD infectious diseases market based on product, technology,
application, end use, and region:
Product Outlook (Revenue, USD Million, 2014
- 2026)
·
Instruments
·
Reagents
·
Software
Technology Outlook (Revenue, USD Million,
2014 - 2026)
·
Immunochemistry
·
Molecular Diagnostics
·
Microbiology
·
Others
Application Outlook (Revenue, USD Million,
2014 - 2026)
·
MRSA
·
Streptococcus
·
Clostridium difficile
·
VRE
·
CRE
·
Respiratory Virus
·
Candida
·
TB and Drug-resistant TB
·
Gastro-intestinal Panel Testing
·
Chlamydia
·
Gonorrhea
·
HPV
·
HIV
·
Hepatitis C
·
Hepatitis B
·
Others
End-use Outlook (Revenue, USD Million, 2014
- 2026)
·
Point of Care
·
Central Laboratories
Regional Outlook (Revenue, USD Million,
2014 - 2026)
·
North America
o
U.S.
o
Canada
·
Europe
o
U.K.
o
Germany
o
Spain
o
France
o
Italy
·
Latin America
o
Brazil
o
Mexico
o
Argentina
·
Asia Pacific
o
Japan
o
China
o
India
o
South Korea
o
Australia
·
Middle East & Africa
o
South Africa
o
Saudi Arabia
o
U.A.E.
Access Press Release of IVD Infectious Diseases Market@
https://www.grandviewresearch.com/press-release/global-ivd-infectious-disease-market
About
Grand View Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco.
The company provides syndicated research reports, customized research reports, and consulting services. To help
clients make informed business decisions, we offer market intelligence studies ensuring relevant and
fact-based research across a range of industries, from technology to chemicals,
materials and healthcare.
No comments:
Post a Comment